New Target Identified for Treating Triple-Negative Breast Cancer
Researchers at the University of California San Diego have uncovered a significant treatment target for triple-negative breast cancer (TNBC), recognized as the most aggressive subtype of breast cancer. The study indicates that a protein known as PUF60 plays a crucial role in promoting the growth and survival of TNBC cells by regulating critical gene splicing processes. Disrupting the function of PUF60 in TNBC models caused extensive errors in gene processing, leading to DNA damage, cell-cycle arrest, and eventual tumor cell death, while sparing healthy cells.
Understanding Triple-Negative Breast Cancer
Triple-negative breast cancer is particularly challenging to treat due to its aggressive nature and lack of response to standard targeted therapies, including immunotherapy and hormone therapy, which are effective in other cancer subtypes. According to the National Cancer Institute, patients with TNBC face a poorer prognosis compared to those with hormone receptor-positive breast cancers, underscoring the urgent need for new therapeutic strategies.
Key Study Findings
The researchers screened over 1,000 RNA-binding proteins in TNBC cells and identified 50 proteins that are critical for TNBC survival, highlighting PUF60 as a leading target. Notable findings include:
- Disruption of PUF60—either by genetic knockdown or through specific mutations—resulted in significant DNA processing errors and increased cell death in TNBC cell models.
- In mouse models of TNBC, the absence of PUF60 led to considerable tumor regression, illustrating its potential role in cancer progression.
- Importantly, healthy breast cells appeared largely unaffected by the loss of PUF60, suggesting a therapeutic window for targeting TNBC specifically.
Therapeutic Implications
This research indicates that targeting PUF60-mediated RNA splicing could be a promising approach for treating TNBC and potentially other cancers associated with replication stress. By identifying PUF60 as a key regulatory protein that cancer cells rely on, the study opens new avenues for drug development aimed specifically at TNBC.
The research, published in Cancer Research, was conducted under the leadership of Corina Antal, PhD, and Gene Yeo, PhD, both professors at UC San Diego School of Medicine and members of the Moores Cancer Center.
Next Steps for Research
While the findings are promising, further research is needed to investigate the potential development of inhibitors targeting PUF60 or its splice-site interactions as effective cancer therapies. These inhibitors could provide a much-needed adaptation in medical strategy for TNBC patients, who currently lack effective treatment options. As emphasized by Dr. Yeo, understanding the specific mechanisms through which PUF60 operates will be crucial in advancing these therapeutic developments.
This research not only sheds light on a potential new treatment for TNBC but also reflects the ongoing need for innovative approaches in cancer therapy. The findings may have profound implications for public health, particularly as TNBC remains a major healthcare challenge worldwide.
